No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PFE240726P29000
- 0.22
- +0.03+15.79%
15min DelayTrading Jul 22 11:33 ET
0.37High0.10Low
0.18Open0.19Pre Close1.45K Volume17.37K Open Interest29.00Strike Price35.79KTurnover38.38%IV2.95%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.22Extrinsic Value100Contract SizeAmericanOptions Type-0.3206Delta0.2830Gamma131.80Leverage Ratio-0.0510Theta-0.0011Rho-42.26Eff Leverage0.0118Vega
Intraday
- 5D
- Daily
News
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
By Adam Clark Eli Lilly and Novo Nordisk are sitting pretty in the pharmaceutical sector due to their weight-loss drugs. While the market has been nervous about potential competition, investors can
Express News | Pfizer Inc : Jefferies Raises Target Price to $34 From $32.
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Pfizer Inc. (PFE): A Good Undervalued Stock to Buy According to Reddit?
Better Dark Horse Weight Loss Drug Stock: Pfizer Vs. Roche
Kamala Harris' Potential Impact on Health Care Stocks
With President Joe Biden earlier Sunday saying he will end his campaign for re-election and endorsing Vice President Kamala Harris, the focus now turns on her positions on issues.
Comments
$Pfizer(PFE.US$ this is the only healthcare share rise today . what’s happening to others
“History Doesn’t Repeat Itself, but It Often Rhymes” – Mark Twain
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful” – Warren Buffett
“Success means being very patient, but aggressive when it’s time.” – Charlie Munger
My previous posts,
I am looking forward to upcoming Fed cuts
Will Nvidia Pullback to 90 ?
$NVIDIA(NVDA.US$ $iShares Russell 2000 ETF(IWM.US$ $MarketAxess(MKTX.US$ $Pfizer(PFE.US$ $Vanguard Real Estate ETF(VNQ.US$ $Global Payments(GPN.US$
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful” – Warren Buffett
“Success means being very patient, but aggressive when it’s time.” – Charlie Munger
My previous posts,
I am looking forward to upcoming Fed cuts
Will Nvidia Pullback to 90 ?
$NVIDIA(NVDA.US$ $iShares Russell 2000 ETF(IWM.US$ $MarketAxess(MKTX.US$ $Pfizer(PFE.US$ $Vanguard Real Estate ETF(VNQ.US$ $Global Payments(GPN.US$
loading...
4
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
Read more